Page 11 - David Ricks News Today

Eli Lillys CEO David Ricks told Reuters on Wednesday that the U.S. drugmaker expects to launch its obesity drug in Indian market as early as next year. ...

Eli Lilly plans to launch its obesity drug, tirzepatide, in India next year. The drug, also known as Mounjaro for diabetes and Zepbound for weight-loss in the U.S., may see authorized generic versions. CEO David Ricks emphasized the need for India to enhance patent protection and eliminate redundant policies to attract global drugmaker investments.

When a rally ends, it is often followed by a few quiet sessions. Yesterday, global indices remained within a small range, resulting in a few shades of red and green, but without excess. Investors are... -February 28, 2024 at 09:42 am EST - MarketScreener

Eli Lilly plans to launch its diabetes and obesity drug, Mounjaro, in India next year. The drug contains tirzepatide and is sold as Zepbound in the US. The global market for GLP-1 receptor agonists, including Mounjaro, Wegovy, and Ozempic, is expected to reach $100 billion by the end of the decade. Lillys drugs as well as Danish rival Novo Nordisks in-demand Wegovy and Ozempic are therapies known as GLP-1 receptor agonists, which were developed to control blood sugar in patients with type 2 diab...

Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D footprint, eyeing India as a pivotal hub for innovation and clinical trials.

This announcement was made by CEO David Ricks in an exclusive interview with Business Today on Wednesday.

"Believe me, everything that this Viking has, [CEO] David Ricks is working on at Lilly," CNBC's Jim Cramer said Tuesday.

No Cookies

BioPharma

Novo Nordisk recently acquired three manufacturing facilities from contract development and manufacturing organization Catalent, in a bold move that has sparked a great deal of debate and some backlash.